PMI urges adult smokers to switch to smoke-free products


Philip Morris International Limited has pleaded with all current adult cigarette smokers who intend to continue to smoke to switch to smokeless products as soon as possible.

Speaking during a webinar on the Smoke Harm Reduction Conference, a former general manager of Philip Morris International, Andre Catantzopoulos, said that a smoke-free future is achievable and the benefits it could bring to those who continue. otherwise to smoke are huge.

He noted that PMI needs the cooperation of governments and civil society to achieve consensus that smoke-free alternatives, when subject to proper oversight and regulation, are part of a policy. healthy tobacco control.

Calantzolopulos said, “Smoking causes serious illness and the best way to avoid the harms of smoking is to never start or stop.

“For decades, tobacco control has focused on stringent fiscal, marketing and other measures to discourage initiation and encourage cessation.”

Calantzolopulos said that although smoking prevalence rates have continued to slowly decline, the World Health Organization predicts that the estimated 1.1 billion people who smoke tobacco products today would largely remain unchanged by 2025, reflecting population growth.

“Nicotine, while it is addictive and not without risk, is not the leading cause of smoking-related illnesses. The main cause is the harmful chemicals released or generated by the combustion of tobacco and contained in the smoke.

Eliminating the combustion of products containing nicotine is the way to considerably reduce their toxicity.

“Thanks to rapid advances in science and technology and PMI’s strong commitment, these products are now a reality,” he said.

Currently, PMI’s smoke-free portfolio includes platforms that heat tobacco, vaporize liquids that contain nicotine, or contain essentially only nicotine, all with no combustion. Their development and manufacture follow high standards of quality and consistency.

He pointed out that the scientific evaluation to justify the harm reduction potential of smokeless products compared to smoking is based on rigorous preclinical and clinical evaluations and sophisticated toxicological systems.


Comments are closed.